Abstract
Both trandolapril and verapamil are effective and widely used antihypertensive agents. The aim of this study was to estimate the efficacy and tolerability of trandolapril/verapamil (Tr/Ve) combination for blood pressure control and renoprotection. PubMed, EMBASE and Cochrane Library were searched for relevant studies. A meta-analysis of all randomized controlled trials (RCTs) meeting the criteria was performed. Twelve RCTs were ultimately included out of 62 studies. (1) Combination versus trandolapril: a greater diastolic blood pressure (DBP) reduction (weighted mean difference (WMD): 3.71, 95% confidence interval (CI): 1.84–5.57); a greater reduction in albuminuria (WMD: 136.77, 95% CI: 12.44–261.09). There were no differences in reduction in systolic blood pressure (SBP), blood pressure response rate or proteinuria. (2) Combination versus verapamil: a greater SBP reduction (WMD: 6.14, 95% CI: 3.59–8.70); a greater DBP reduction (WMD: 2.49, 95% CI: 0.81–4.17); a greater reduction in proteinuria (standardized mean difference: 0.84, 95% CI: 0.22–1.45); a greater reduction in albuminuria (WMD: 255.00, 95% CI: 119.26–390.74). (3) Incidence of all-cause adverse events (AEs) was comparable between combination and monotherapy. The present meta-analysis indicates that Tr/Ve combination provides a superior blood pressure control and a favourable renoprotective effect without an increase of overall AEs than verapamil monotherapy. The combination also shows a slight advantage over trandolapril monotherapy by reducing DBP and albuminuria to a greater extent.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Whitworth JA . 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983–1992.
Chobanian AV, Bakris GL, Black HR . The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. Hypertension 2003; 42: 1206.
Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A . Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65 (6): 1991–2002.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17 (1): 1–12.
Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009].
Bakris GL, Weir MR, DeQuattro V, McMahon FG . Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54 (4): 1283–1289.
DeQuattro V, Lee D . Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. Am J Hypertens 1997; 10 (7 Part 2): 138S–145S.
Karlberg BE, Andrup M, Oden A . Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Blood Press 2000; 9 (2–3): 140–145.
Messerli F, Frishman WH, Elliott WJ . Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. Am J Hypertens 1998; 11 (3 Part 1): 322–327.
PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens 2002; 20 (4): 729–737.
Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodriguez-Lopez L, Escalante-Acosta BA . The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens 2008; 30 (7): 682–688.
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351 (19): 1941–1951.
Ruilope LM, Usan L, Segura J, Bakris GL . Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResion Arterial en DIabeticos tipo Dos) study. J Hypertens 2004; 22 (1): 217–222.
Scholze J, Zilles P, Compagnone D . Verapamil SR and trandolapril combination therapy in hypertension—a clinical trial of factorial design. German Hypertension Study Group. Br J Clin Pharmacol 1998; 45 (5): 491–495.
Topouchian J, Asmar R, Sayegh F, Rudnicki A, Benetos A, Bacri AM et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke 1999; 30 (5): 1056–1064.
Veratran Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: the Veratran Study. Am J Hypertens 1997; 10 (5 Part 1): 492–499.
Versari D, Virdis A, Ghiadoni L, Daghini E, Duranti E, Masi S et al. Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. Atherosclerosis 2009; 205 (1): 214–220.
Bakris GL, Ritz E . The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich) 2009; 11 (3): 144–147.
Rubio-Guerra AF, Lozano-Nuevo JJ, Vargas-Ayala G, Rodriguez-Lopez L, Ramos-Brizuela LM, Escalante-Acosta BA . Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy. Clin Exp Hypertens 2006; 28 (7): 619–624.
Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D . Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987; 32 (1): 78–83.
Smith AC, Toto R, Bakris GL . Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54 (3): 889–896.
Tarif N, Bakris GL . Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997; 12 (11): 2244–2250.
Michelle A, Faulkner DEH . Fixed-dose combination antihypertensive therapy with trandolapril/verapamil: a meta-analytic comparison against monotherapy. Am J Hypertens 2004; 17 (5 Suppl1): S105.
Quinones-Galvan A, Pucciarelli A, Ciociaro D, Masoni A, Franzoni F, Natali A et al. Metabolic effects of combined antihypertensive treatment in patients with essential hypertension. J Cardiovasc Pharmacol 2002; 40 (6): 916–921.
Fernandez R, Puig JG, Rodriguez-Perez JC, Garrido J, Redon J . Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15 (12): 849–856.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Zou, Z., Xu, FY., Wang, L. et al. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials. J Hum Hypertens 25, 203–210 (2011). https://doi.org/10.1038/jhh.2010.60
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2010.60
Keywords
This article is cited by
-
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease
High Blood Pressure & Cardiovascular Prevention (2020)
-
Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria
Journal of Human Hypertension (2012)
-
Antihypertensive Effects of Olmesartan Compared with Other Angiotensin Receptor Blockers
American Journal of Cardiovascular Drugs (2012)